Comparative Pharmacology
Head-to-head clinical analysis: LUMISIGHT versus PORCINE SECRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMISIGHT versus PORCINE SECRETIN.
LUMISIGHT vs PORCINE SECRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMISIGHT is a pegolaptamer that binds to and inhibits the vascular endothelial growth factor (VEGF), thereby reducing angiogenesis and vascular permeability in ocular tissues.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
1 mg administered intravenously as a single dose prior to identification of suspected malignant lesions during cystoscopy.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in patients with normal renal function; prolonged up to 12-18 hours in moderate to severe renal impairment.
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
Primarily renal excretion of unchanged drug (60-70%) and hepatic metabolism with biliary/fecal elimination of metabolites (20-25%). Approximately 5-10% is excreted unchanged in feces.
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent